[3-cyano-4-(2-methoxyphenyl)-6-phenylpyridin-2-ylsulfanyl]acetic acid | 312757-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [3-cyano-4-(2-methoxyphenyl)-6-phenylpyridin-2-ylsulfanyl]acetic acid
• 英文别名: 2-[[3-Cyano-4-(2-methoxyphenyl)-6-phenyl-2-pyridinyl]thio]acetic acid；2-[3-cyano-4-(2-methoxyphenyl)-6-phenylpyridin-2-yl]sulfanylacetic acid
• CAS: 312757-90-7
• 化学式: C₂₁H₁₆N₂O₃S
• 分子量: 376.436
• InChiKey: HXHZNFAFHFRUIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  苯甲酰三氟丙酮 在 N-甲基吗啉 、 potassium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 [3-cyano-4-(2-methoxyphenyl)-6-phenylpyridin-2-ylsulfanyl]acetic acid
  参考文献：
  名称：

  Synthesis of 4-aryl-6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitriles by three-component condensation of aromatic aldehydes with cyanothioacetamide and 4,4,4-trifluoro-1-phenylbutane-1,3-dione

  摘要：

  4-Aryl-6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitriles were synthesized by three-component condensation of aromatic aldehydes with cyanothioacetamide and 4,4,4-trifluoro-1-phenylbutane-1,3-dione. The reaction involved initial formation of Michael adducts which underwent acyl cleavage.

  DOI：

  10.1134/s1070428011100150

文献信息

• ANT-LIGANDS MOLECULES AND BIOLOGICAL APPLICATIONS
  申请人：Borgne-Sanchez Annie

  公开号：US20110086865A1

  公开（公告）日：2011-04-14

  The invention relates to molecules ANT-ligands having a substituted nitrogeneous heterocycle A wherein —A is a substituted pyrazinone of formula I wherein R1 is —(CH 2 ) n —CO—OH; —(CH 2 ) n —CO—OR; —(CH 2 ) n —CO—NHR; —(CH 2 ) n —CO—N(R, R′); —(CH 2 ) n —OH; —(CH 2 ) n —OR; —(CH 2 ) n —OAr; —(CH 2 ) n —C(R,R′) —(CH 2 ) n —OH, R and R′, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het. representing an heterocyclic radical with one or several hetero atoms selected between N, S and O, said phenyl or heterocycle being optionally substituted by one or several atoms, groups or radicals selected from halogen atoms such as Cl, Br, I, or halogenated groups such as —CCl 3 or —CF 3 ; one or several —OH, —OR, —COOH or —COOR groups; a phenyl; a linear or branched C1-C12 alkyl radical; —NH—COR; or —CN; said groups occupying the same or different positions on the phenyl or heterocyclic radical; a linear or branched C1-C12 alkyl radical; a linear or branched C2-C12 alkylene radical; —(CH 2 ) n —C3-C6 cycloalkyl radical; —(CH 2 ) n Ar or —(CH 2 ) n Het.; —(CH 2 ) n —NH—CO—R; —(CH 2 ) n —NH 2 ; —(CH 2 ) n —N(R,R′); —(CH 2 ) n —NH—CO—OH; —(CH 2 ) n —NH—CO—OR; —NH—(CH 2 ) n —CO—OH; —NH—(CH 2 ) n —CO—OR; R2 is —(CH 2 ) n -Ar, Ar being such as above defined and being optionally substituted such as above defined; a linear or branched C1-C12 alkyl or C2-C12 alkylene radical with one or several double bonds; —(CH 2 ) n —OH; —(CH 2 ) n —OR; —(CH 2 ) n —CO—Het; —(CH 2 ) n —NH—CO—R; —(CH 2 ) n —NH 2 ; —(CH 2 ) n —N(R,R′); —(CH 2 ) n —CO—OH; —(CH 2 ) n —CO—OR; a linear or branched C1-C12 alkyl radical; —(CH 2 ) n —C(R)=CH—C (R)=CH 2 , R3 forms a phenyl or an heterocyclic condensed group with the two adjacent carbons of the pyrazinone residue, said condensed group being optionally substituted such as above defined for Ar and Het.; and/or condensed to a cyclohexyl or oxanyl group, in turn optionally substituted such as above defined for Ar; n is 0 or an integer from 1 to 5; or A is a substituted pyrazine of formula II wherein R 4 is a —CO—NH—Ar radical, optionally substituted such as above defined; R5 forms a phenyl or heterocyclic group condensed to the two adjacent carbon groups of the pyrazine residue, said phenyl or heterocyclic group being optionally substituted such as above defined, and Ar being such as above defined with respect to formula I or A is a substituted pyridine group of formula III wherein, Ar and R2 are as above defined with respect to formula I.

  该发明涉及具有取代氮杂环A的分子ANT配体，其中—A是具有以下式I的取代吡嗪酮：其中R1是—(CH2)n—CO—OH;—(CH2)n—CO—OR;—(CH2)n—CO—NHR;—(CH2)n—CO—N(R, R′);—(CH2)n—OH;—(CH2)n—OR;—(CH2)n—OAr;—(CH2)n—C(R,R′)—(CH2)n—OH，上述基团中的R和R′相同或不同，代表H或C1-C12烷基或环烷基基团；Ar是苯基或Het.，Het.代表一个杂原子为N、S和O的杂环基团，所述苯基或杂环基团可以选择性地被一个或多个原子、基团或基团取代，所选基团包括卤原子如Cl、Br、I，或卤代基团如—CCl3或—CF3；一个或多个—OH、—OR、—COOH或—COOR基团；苯基；线性或支链的C1-C12烷基基团；—NH—COR；或—CN；这些基团可以占据苯基或杂环基团上的相同或不同位置；线性或支链的C1-C12烷基基团；线性或支链的C2-C12亚烯基基团；—(CH2)n—C3-C6环烷基基团；—(CH2)nAr或—(CH2)nHet.；—(CH2)n—NH—CO—R；—(CH2)n—NH2；—(CH2)n—N(R,R′)；—(CH2)n—NH—CO—OH；—(CH2)n—NH—CO—OR；—NH—(CH2)n—CO—OH；—NH—(CH2)n—CO—OR；R2是—(CH2)n-Ar，Ar如上定义，可以选择性地被如上定义取代；线性或支链的C1-C12烷基或C2-C12亚烯基基团，带有一个或多个双键；—(CH2)n—OH；—(CH2)n—OR；—(CH2)n—CO—Het；—(CH2)n—NH—CO—R；—(CH2)n—NH2；—(CH2)n—N(R,R′)；—(CH2)n—CO—OH；—(CH2)n—CO—OR；线性或支链的C1-C12烷基基团；—(CH2)n—C(R)=CH—C(R)=CH2；R3形成一个苯基或与吡嗪酮残基的两个相邻碳原子形成杂环的紧凑基团，所述紧凑基团可以选择性地被如上定义的Ar和Het取代；和/或紧凑为一个环己基或氧杂环基团，进一步可以选择性地被如上定义的Ar取代；n为0或1到5的整数；或A是具有以下式II的取代吡嗪：其中R4是一个—CO—NH—Ar基团，可以选择性地被如上定义取代；R5形成一个苯基或杂环基团，紧凑到吡嗪残基的两个相邻碳基团，所述苯基或杂环基团可以选择性地被如上定义取代，Ar如上定义，关于式I的定义；或A是具有以下式III的取代吡啶基团：其中，Ar和R2如上定义，关于式I的定义。
• Glyoxalase inhibitors
  申请人：Ashton Mark

  公开号：US20070015799A1

  公开（公告）日：2007-01-18

  This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase 1. Wherein X is N or CH. R 2 is H, CF 3 ; or optionally substituted C 5-6 aryl, C 3-7 cycloalkyl, C 5-7 heterocyclyl. R 3 is H; or optionally substituted C 5-6 aryl, C 3-7 cycloalkyl, C 5-7 heterocyclyl. Alternatively R 2 and R 3 together form an optionally substituted C 3-4 alkylene group wherein L 3 and L 4 are single bonds thus forming a C 5-6 ring fused with the aromatic ring to which L 3 and L 4 are attached. L 3 and L 4 are independently selected from a single bond, optionally substituted C 1-4 alkylene, -L 9 YN(OH)C(═O)L 10 - and -L 9 C(═O)N(OH)YL 10 -, wherein L 9 and L 10 are independently selected from optionally substituted C 1-4 alkylene, C 5-6 arylene, C 1-4 alkylene-C 5-6 arylene and a single bond, wherein Y is NH or a single bond.

  本发明涉及式(I)的化合物，它们是乙二醛酶I抑制剂，包括此类化合物的药物盐或组合物，以及使用这种组合物和化合物来治疗通过抑制乙二醛酶1缓解的各种疾病。其中X是N或CH。R2为H、CF3；或者是可选取代的C5-6芳基、C3-7环烷基、C5-7杂环基。R3为H；或者是可选取代的C5-6芳基、C3-7环烷基、C5-7杂环基。或者R2和R3一起形成一个可选取代的C3-4烷基，其中L3和L4是单键，从而形成一个与L3和L4连接的芳环。L3和L4分别独立选择自单键、可选取代的C1-4烷基、-L9YN(OH)C(═O)L10-和-L9C(═O)N(OH)YL10-，其中L9和L10分别独立选择自可选取代的C1-4烷基、C5-6芳基、C1-4烷基-C5-6芳基和单键，其中Y为NH或单键。
• US8809346B2
  申请人：——

  公开号：US8809346B2

  公开（公告）日：2014-08-19
• US9657031B2
  申请人：——

  公开号：US9657031B2

  公开（公告）日：2017-05-23
• Synthesis of 4-aryl-6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitriles by three-component condensation of aromatic aldehydes with cyanothioacetamide and 4,4,4-trifluoro-1-phenylbutane-1,3-dione
  作者：V. D. Dyachenko

  DOI：10.1134/s1070428011100150

  日期：2011.10

  4-Aryl-6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitriles were synthesized by three-component condensation of aromatic aldehydes with cyanothioacetamide and 4,4,4-trifluoro-1-phenylbutane-1,3-dione. The reaction involved initial formation of Michael adducts which underwent acyl cleavage.